Modernism played an undeniable role in the renewal of architectural ideals, contributing a new attitude toward understanding ...

HealthDay News — The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu. This ...

Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in Phase 3 clinical trials, with the potential to be the first approved ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of ...

The American pharmaceutical company Moderna is developing an mRNA-based vaccine candidate for norovirus, designated as mRNA-1403. This vaccine is designed to protect against multiple norovirus ...

Following four straight sessions of gains, Moderna (NASDAQ:MRNA) shares continued to trade higher in the premarket on Friday after the company received a tender to supply its COVID-19 vaccine in ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the ...

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial investigating a ...

Biotechnology company Moderna (NASDAQ:MRNA) gained the spotlight in the medical sector as a leader in the race toward a COVID-19 vaccine. Its messenger RNA (mRNA) technology garnered acclaim as a ...

AND KHIREE, WHAT DID CASA TELL YOU ABOUT THIS PLAN? WELL, OFFICIALS WITH CASA SAID THAT THEY’RE READY TO HELP FAMILIES THAT WILL BE IMPACTED BY THESE EXECUTIVE ORDERS. THEY SAID THAT THEY’RE ...